A drug newly approved for a certain type of advanced prostate cancer is a game-changer, according to Providence Saint John’s Health Center oncologist Przemyslaw Twardowski, M.D., who co-authored a study published last week in the New England Journal of Medicine. The Federal Drug Administration on May 19 approved olaparib, an oral medication previously restricted for […]